MNKD MannKind Corporation - Common Stock
$4,26
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 5, 2026
52 Haftlık Aralık
$2–$7
47% of range
Analist Derecelendirmesi
BUY
14 analysts
Fiyat Hedefi
$8
+87% upside
P/E (TTM)
212.9
ROE
-11.1%
Net Kâr Marjı
1.7%
MannKind Corporation - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Devamını oku
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.
History
Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).
The FDA approved Afrezza on June 27, 2014.
On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.
In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.
Products and product candidates
The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.
Leadership
Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.
In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.
Facilities
MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
MNKD Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$4.26
Piyasa Değeri
$1.31B
P/E (TTM)
212.9
EPS (TTM)
$0.02
Gelir (TTM)
$349M
Temettü Verimi
—
ROE
-11.1%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$2 – $7
MNKD Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$349M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$0.02
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
$14M
2018-12-31
→
2025-12-31
Marjlar
1.7%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
MNKD
Akran Ortalaması
P/E (TTM)
212.9
—
P/S (TTM) (F/S (TTM))
3.8
10.7
P/B (F/D)
-25.7
5.2
Price / FCF (Fiyat / Serbest Nakit Akışı)
95.7
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
MNKD
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
11.1%
—
Net Profit Margin (Net Kâr Marjı)
1.7%
-140.3%
ROA
0.99%
-44.7%
ROE
-11.1%
-51.5%
ROIC
-316.9%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
MNKD
Akran Ortalaması
Current Ratio (Cari Oran)
1.7
9.5
Quick Ratio (Cari Oran)
1.2
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
MNKD
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
22.2%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
51.8%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
39.9%
—
EPS YoY (EPS YB)
-80.0%
—
Net Income YoY (Net Gelir Yıllık Bazda)
-78.8%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
MNKD
Akran Ortalaması
MNKD Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
14 analist
- Güçlü Al 4 28,6%
- Al 8 57,1%
- Tut 2 14,3%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
8 analist · 2026-08-17
Medyan
$7.50
← Tüm hedeflerin altında
$4.26
Düşük
$4.75
Yüksek
$13.00
Medyan hedef
$7.50
+76,2%
Ortalama hedef
$7.97
+87,2%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.03%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $-0.06 | $-0.00 | -0.06% |
| 31 Mart 2026 | $-0.05 | $-0.00 | -0.05% |
| 31 Aralık 2025 | $-0.05 | $0.01 | -0.06% |
| 30 Eylül 2025 | $0.07 | $0.02 | 0.05% |
| 30 Haziran 2025 | $0.00 | $0.05 | -0.05% |
| 31 Mart 2025 | $0.04 | $0.04 | -0.00% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | — |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | — |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | — |
| GLUE | $1.03B | — | 63.5% | -31.2% | -15.4% | — |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | — |
| CRVS | $575M | -14.5 | — | — | -21.6% | — |
| REPL | $633M | -2.3 | — | — | -146.2% | — |
| VOR | $506M | -0.2 | — | — | 83.4% | — |
| SANA | $1.09B | -4.2 | — | — | -172.3% | — |
| SVRA | $1.23B | -11.4 | — | — | -73.4% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Cost of Revenue | $27M | $17M | $21M | $16M | $17M | $15M | $20M | $19M | $17M | $17M | $65M | · | |
| SG&A Expense | $144M | $94M | $94M | $91M | $32M | $25M | $75M | $80M | $75M | $47M | $41M | $79M | |
| Operating Expenses | $88M | $77M | $63M | $57M | $39M | $25M | $108M | $104M | $120M | $107M | $345M | $180M | |
| Operating Income | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-108M | $67M | $-345M | $-180M | |
| Interest Expense | · | · | $15M | $15M | $15M | · | · | · | · | · | $24M | $20M | |
| Interest Income | $8M | $13M | $6M | $3M | $112.0K | $167.0K | $997.0K | $501.0K | $293.0K | $85.0K | $18.0K | $9.0K | |
| Other Non-op | $-1M | $32.0K | $122.0K | $-102.0K | $-239.0K | $23.0K | $-926.0K | $-437.0K | $13.0K | $-597.0K | $1M | $2M | |
| Pretax Income | $1M | $31M | $-10M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Income Tax | $-4M | $3M | $2M | $0 | $0 | $-218.0K | $0 | $240.0K | $51.0K | $0 | $0 | $0 | |
| Net Income | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.37 | $-4.54 | $-2.57 | |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 | |
| Shares (Basic) | 305,639,000 | 274,415,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,053,000 | 81,233,000 | 77,045,000 | |
| Shares (Diluted) | 314,112,000 | 283,844,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,085,000 | 81,233,000 | 77,045,000 | |
| EBITDA | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-106M | · | $-334M | $-170M |
Bilanço 28
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75M | $46M | $238M | $70M | $124M | $67M | $30M | $71M | $44M | $23M | $59M | $121M | |
| Short-term Investments | $96M | $151M | $57M | $101M | $80M | $0 | $20M | · | · | · | · | · | |
| Receivables | $38M | $12M | $15M | $17M | $5M | $4M | $4M | $4M | $3M | $302.0K | $23.0K | $50M | |
| Inventory | $35M | $28M | $29M | $22M | $7M | $5M | $4M | $4M | $3M | $2M | · | $10M | |
| Prepaid Expense | $47M | $31M | $35M | $25M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $20M | |
| Current Assets | $292M | $268M | $373M | $235M | $219M | $79M | $61M | $82M | $57M | $77M | $77M | $201M | |
| PP&E (Net) | $82M | $85M | $84M | $45M | $37M | $26M | $27M | $26M | $27M | $29M | $49M | $192M | |
| PP&E (Gross) | $196M | $192M | $186M | $144M | $134M | $123M | $122M | $126M | $128M | $129M | $168M | $310M | |
| Accum. Depreciation | $114M | $107M | $102M | $99M | $98M | $97M | $95M | $100M | $101M | $100M | $120M | $118M | |
| Goodwill | $68M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $1M | $1M | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $27M | $7M | $10M | $8M | $3M | $6M | $249.0K | $437.0K | $648.0K | $1M | $848.0K | |
| Total Assets | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Accounts Payable | $9M | $7M | $10M | $11M | $7M | $6M | $5M | $5M | $7M | $3M | $16M | $7M | |
| Accrued Liabilities | $65M | $40M | $42M | $36M | $27M | $20M | $16M | $15M | $12M | $8M | $8M | $26M | |
| Short-term Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Current Liabilities | $171M | $82M | $104M | $67M | $48M | $74M | $66M | $75M | $88M | $92M | $268M | $403M | |
| Capital Leases | $11M | $12M | $4M | $5M | $1M | $1M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $5M | · | · | · | · | · | $15M | $12M | |
| Total Liabilities | $843M | $473M | $721M | $546M | $531M | $289M | $284M | $283M | $299M | $291M | $477M | $468M | |
| Long-term Debt | $355M | $36M | $269M | $273M | $281M | $122M | $119M | $102M | $157M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $4M | $4M | |
| Retained Earnings | $-3.20B | $-3.20B | $-3.23B | $-3.22B | $-3.13B | $-3.05B | $-2.99B | $-2.94B | $-2.85B | $-2.74B | $-2.86B | $-2.49B | |
| AOCI | $115.0K | $1M | · | · | · | · | $-19.0K | $-19.0K | $-18.0K | $-24.0K | $-20.0K | $-14.0K | |
| Stockholders' Equity | $-51M | $-79M | $-246M | $-251M | $-209M | $-180M | $-191M | $-175M | $-215M | $-184M | $-350M | $-74M | |
| Liabilities + Equity | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Shares Outstanding | 307,832,587 | 302,959,782 | 270,034,495 | 263,793,305 | 251,477,562 | 242,117,089 | 211,787,573 | 187,029,967 | 119,053,414 | 95,680,831 | 85,734,188 | 406,059,089 |
Nakit Akışı 18
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $7M | $5M | $3M | $2M | $2M | $972.0K | $3M | $2M | $2M | $11M | $10M | |
| Stock-based Comp | $24M | $21M | $18M | $13M | $12M | $7M | $6M | $7M | $5M | $5M | $9M | $49M | |
| Deferred Tax | $-19M | $4M | $7M | $-10M | $-20M | $-5M | $-5M | $-11M | $-260M | $48M | $-80M | $-66M | |
| Amort. of Intangibles | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $6M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | $306M | · | $291M | $144M | |
| Operating Cash Flow | $18M | $43M | $34M | $-81M | $-62M | $-28M | $-88M | $-38M | $-65M | $-78M | $-57M | $4M | |
| CapEx | $5M | $10M | $42M | $8M | $11M | $801.0K | $3M | $354.0K | · | $1M | $10M | $24M | |
| Investing Cash Flow | $-305M | $-97M | $-2M | $5M | $-152M | $15M | $-23M | $-234.0K | $17M | $-1M | · | · | |
| Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | $20M | |
| Net Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $564.0K | $893.0K | $28M | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $564.0K | · | $28M | · | |
| Financing Cash Flow | $315M | $-137M | $137M | $21M | $270M | $50M | $70M | $61M | $74M | $43M | · | · | |
| Net Change in Cash | $29M | $-191M | $169M | $-54M | $57M | $37M | $-41M | $23M | $25M | $-36M | $-62M | $50M | |
| Taxes Paid | $2M | $4M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $14M | $33M | $-8M | $-88M | $-73M | $-29M | $-91M | $-38M | · | · | $-68M | $-20M | |
| Levered FCF | · | · | $-26M | $-98M | · | · | · | · | · | · | $-92M | · |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -921.1% | · | · | · | |
| Net Margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | · | · | · | |
| Pretax Margin | 0.40% | 10.7% | -5.2% | -87.6% | -107.3% | -88.2% | -82.3% | -311.3% | -998.6% | · | · | · | |
| EBITDA Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -905.8% | · | · | · | |
| ROA | 0.99% | 6.3% | -3.1% | -28.4% | -37.7% | -56.6% | -51.5% | -90.5% | -122.4% | · | -141.5% | -60.8% | |
| ROE | -11.1% | -19.1% | 4.8% | 35.8% | 41.1% | 31.2% | 27.7% | 45.7% | 58.9% | · | 173.8% | 379.7% | |
| ROIC | -316.9% | -83.2% | -4.1% | 25.6% | 22.5% | 26.5% | 24.0% | 43.9% | 50.4% | · | 98.4% | · |
Likidite ve Solventlik 4
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 | 1.1 | 0.9 | 1.1 | 0.7 | · | 0.3 | 0.5 | |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 | 1.0 | 0.8 | 1.0 | 0.5 | · | 0.2 | 0.4 | |
| Debt / Equity | · | · | · | · | · | · | -0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | 0.6 | -6.7 | · | · | · | · | · | · | -14.3 | -8.8 |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.1 | · | 0.0 | · | |
| Inventory Turnover | 0.8 | 0.6 | 0.8 | 1.1 | 2.8 | 3.3 | 5.2 | 6.2 | 6.9 | · | · | · | |
| Receivables Turnover | 13.9 | 21.4 | 12.6 | 9.3 | 16.4 | 16.9 | 16.7 | 8.2 | 7.6 | · | 0.0 | · |
Büyüme Oranları 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 51.8% | 55.8% | 45.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 39.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -80.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -78.8% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 13
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Net Income TTM | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Market Cap | $1.75B | $1.95B | $983M | $1.39B | $1.10B | $758M | $273M | $198M | $276M | · | $3.11B | $10.60B | |
| Enterprise Value | · | · | · | · | · | · | $228M | · | · | · | · | · | |
| P/E | 283.5 | 64.3 | -91.0 | -15.5 | -13.7 | -12.0 | -2.0 | -1.8 | -2.1 | 2.4 | -1.6 | -10.2 | |
| P/S | 5.0 | 6.8 | 4.9 | 13.9 | 14.6 | 11.6 | 4.3 | 7.1 | 23.5 | · | · | · | |
| P/B | -34.2 | -24.7 | -4.0 | -5.5 | -5.2 | -4.2 | -1.4 | -1.1 | -1.3 | · | -8.9 | -143.7 | |
| P / Cash Flow | 95.6 | 45.8 | 28.8 | -17.2 | -17.8 | -26.9 | -3.1 | -5.3 | -4.3 | · | -54.3 | 2593.8 | |
| P / FCF | 127.5 | 59.4 | -117.8 | -15.7 | -15.0 | -26.2 | -3.0 | -5.2 | · | · | -46.0 | -529.6 | |
| EV / EBITDA | · | · | · | · | · | · | -5.1 | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -2.5 | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 3.6 | · | · | · | · | · | |
| Earnings Yield | 0.35% | 1.6% | -1.1% | -6.5% | -7.3% | -8.3% | -48.8% | -56.6% | -48.7% | 42.5% | -62.6% | -9.8% |
Gelir Tablosu 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $90M | $112M | $82M | $77M | $78M | $77M | $70M | $72M | $66M | $58M | $51M | $49M | $41M | $36M | $33M | |
| Cost of Revenue | $14M | $8M | $14M | $4M | $5M | $4M | $5M | $3M | $6M | $4M | $6M | $4M | $5M | $6M | $4M | $5M | |
| SG&A Expense | $58M | $54M | $58M | $29M | $32M | $25M | $24M | $24M | $24M | $22M | $61M | $11M | $12M | $11M | $64M | $9M | |
| Operating Expenses | $30M | $92M | $-103M | $63M | $21M | $56M | $-86M | $57M | $56M | $50M | $18M | $14M | $14M | $16M | $16M | $17M | |
| Operating Income | $-350.0K | $-2M | $-8M | $19M | $5M | $22M | $26M | $13M | $17M | $17M | $8M | $5M | $2M | $-6M | $-13M | $-10M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $3M | · | $3M | $7M | $3M | · | $3M | |
| Interest Income | $1M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $663.0K | |
| Other Non-op | $-5M | $-3M | $23M | $-11M | $-4M | $-9M | $24M | $110.0K | $-18M | $-6M | $-164.0K | $318.0K | $-143.0K | $111.0K | $105.0K | $-207.0K | |
| Pretax Income | $-19M | $-16M | $-21M | $8M | $940.0K | $14M | $8M | $13M | $-2M | $11M | $3M | $2M | $-5M | $-10M | $-18M | $-14M | |
| Income Tax | $-106.0K | $253.0K | $-5M | $-204.0K | $272.0K | $459.0K | $1M | $1M | $323.0K | $264.0K | $2M | $0 | $0 | $0 | · | $0 | |
| Net Income | $-19M | $-17M | $-16M | $8M | $668.0K | $13M | $7M | $12M | $-2M | $11M | $1M | $2M | $-5M | $-10M | $-18M | $-14M | |
| EPS (Basic) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| EPS (Diluted) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| Shares (Basic) | 309,191,000 | 308,267,000 | -609,602,000 | 306,806,000 | 304,954,000 | 303,481,000 | -543,995,000 | 274,998,000 | 273,056,000 | 270,356,000 | -531,313,000 | 268,732,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| Shares (Diluted) | 309,191,000 | 308,267,000 | -629,907,000 | 311,638,000 | 311,484,000 | 320,897,000 | -598,638,000 | 284,693,000 | 273,056,000 | 324,733,000 | -586,351,000 | 323,770,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| EBITDA | · | $-2M | · | $19M | $5M | $22M | · | $13M | $17M | $17M | · | $5M | $2M | $-6M | · | $-10M |
Bilanço 25
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $75M | $127M | $57M | $47M | $46M | $62M | $97M | $193M | · | $83M | $86M | $86M | · | $54M | |
| Short-term Investments | $58M | $81M | $96M | $133M | $122M | $134M | $151M | $189M | $151M | $107M | · | $58M | $58M | $80M | · | $111M | |
| Receivables | $43M | $28M | $38M | $17M | $27M | $29M | $12M | $18M | $23M | $20M | · | $22M | $28M | $20M | · | $23M | |
| Inventory | $44M | $49M | $35M | $27M | $28M | $29M | $28M | $27M | $25M | $26M | · | $27M | $25M | $22M | · | $18M | |
| Prepaid Expense | $47M | $40M | $47M | $54M | $44M | $34M | $31M | $31M | $30M | $36M | · | $36M | $33M | $15M | · | $12M | |
| Current Assets | $246M | $251M | $292M | $359M | $279M | $274M | $268M | $328M | $326M | $383M | · | $226M | $230M | $223M | · | $218M | |
| PP&E (Net) | $85M | $83M | $82M | $83M | $83M | $84M | $85M | $85M | $85M | $84M | · | $80M | $70M | $55M | · | $41M | |
| PP&E (Gross) | $203M | $198M | $196M | $195M | $194M | $192M | $192M | $192M | $190M | $186M | · | $182M | $170M | $154M | · | $140M | |
| Accum. Depreciation | $118M | $116M | $114M | $113M | $111M | $109M | $107M | $107M | $105M | $103M | · | $101M | $100M | $100M | · | $99M | |
| Goodwill | $68M | $68M | $68M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $3M | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-current Assets | $17M | $22M | $20M | $19M | $20M | $28M | $27M | $26M | $16M | $7M | · | $8M | $8M | $16M | · | $17M | |
| Total Assets | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Accounts Payable | $11M | $16M | $9M | $7M | $10M | $5M | $7M | $6M | $10M | $7M | · | $17M | $17M | $14M | · | $10M | |
| Accrued Liabilities | $61M | $59M | $65M | $31M | $31M | $40M | $40M | $37M | $41M | $42M | · | $32M | $37M | $33M | · | $30M | |
| Current Liabilities | $143M | $135M | $171M | $109M | $112M | $116M | $82M | $72M | $80M | $100M | · | $96M | $97M | $82M | · | $60M | |
| Capital Leases | $10M | $10M | $11M | $10M | $11M | $11M | $12M | $12M | $3M | $4M | · | $4M | $5M | $5M | · | $6M | |
| Total Liabilities | $800M | $804M | $843M | $539M | $467M | $469M | $473M | $674M | $670M | $711M | · | $572M | $574M | $554M | · | $532M | |
| Long-term Debt | $319M | $319M | $355M | $110M | $36M | $36M | $36M | $228M | $228M | $264M | · | $273M | $274M | $274M | · | $273M | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Retained Earnings | $-3.23B | $-3.21B | $-3.20B | $-3.18B | $-3.19B | $-3.19B | $-3.20B | $-3.21B | $-3.22B | $-3.22B | · | $-3.23B | $-3.23B | $-3.23B | · | $-3.20B | |
| AOCI | $-19.0K | $-4.0K | $115.0K | $137.0K | $1M | $1M | $1M | $588.0K | · | · | · | $443.0K | $443.0K | · | · | $-1M | |
| Stockholders' Equity | $-67M | $-59M | $-51M | $-45M | $-55M | $-59M | $-79M | $-210M | $-226M | $-230M | $-246M | $-252M | $-260M | $-255M | $-251M | $-238M | |
| Liabilities + Equity | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Shares Outstanding | 309,911,682 | 308,907,331 | 307,832,587 | 307,027,189 | 306,332,133 | 303,918,969 | 302,959,782 | 275,775,038 | 274,467,247 | 270,801,781 | · | 269,543,539 | 268,235,145 | 264,278,760 | · | 263,156,165 |
Nakit Akışı 11
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $-427.0K | |
| Stock-based Comp | $10M | $6M | $7M | $4M | $8M | $5M | $6M | $5M | $6M | $4M | $4M | $5M | $6M | $4M | $3M | $4M | |
| Amort. of Intangibles | $4M | $4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-18M | $-5M | $-8M | $24M | $9M | $-6M | $23M | $9M | $4M | $7M | $22M | $9M | $3M | $1M | $-2M | $-28M | |
| CapEx | $5M | $2M | $2M | $1M | $1M | $330.0K | $3M | $1M | $3M | $2M | $6M | $11M | $17M | $8M | $5M | $271.0K | |
| Investing Cash Flow | $18M | $19M | $-292M | $-25M | $6M | $6M | $48M | $-41M | $-55M | $-48M | $-8M | $-12M | $4M | $14M | $15M | $27M | |
| Financing Cash Flow | $559.0K | $-35M | $247M | $72M | $-6M | $1M | $-87M | $-2M | $-45M | $-3M | $142M | $-283.0K | $-6M | $1M | $3M | $20M | |
| Net Change in Cash | $97.0K | $-22M | $-53M | $70M | $10M | $975.0K | $-16M | $-34M | $-96M | $-45M | $155M | $-3M | $315.0K | $16M | $15M | $19M | |
| Taxes Paid | $753.0K | $63.0K | $549.0K | $80.0K | $869.0K | $207.0K | $2M | $236.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-7M | · | · | · | $-7M | · | · | · | $4M | · | · | · | $-7M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2M | · | · | · | $-10M | · | · |
Kârlılık 7
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| Net Margin | · | -18.4% | · | 9.7% | 0.87% | 16.8% | · | 16.5% | -2.8% | 16.0% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| Pretax Margin | · | -18.1% | · | 9.5% | 1.2% | 17.4% | · | 18.4% | -2.3% | 16.4% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| EBITDA Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| ROA | · | -2.9% | · | 1.7% | 0.16% | 2.9% | · | 2.9% | -0.53% | 2.7% | · | 0.56% | -1.8% | -3.2% | · | -5.4% | |
| ROE | · | 28.2% | · | -6.3% | -0.48% | -9.1% | · | -5.0% | 0.83% | -4.4% | · | -0.70% | 2.1% | 4.0% | · | 6.8% | |
| ROIC | · | 2.9% | · | -43.5% | -6.8% | -36.8% | · | -5.5% | -8.8% | -7.1% | · | -2.0% | -0.66% | 2.4% | · | · |
Likidite ve Solventlik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 1.9 | · | 3.3 | 2.5 | 2.4 | · | 4.5 | 4.1 | 3.8 | · | 2.3 | 2.4 | 2.7 | · | 3.7 | |
| Quick Ratio | · | 1.2 | · | 2.5 | 1.8 | 1.8 | · | 3.7 | 3.4 | 3.2 | · | 1.7 | 1.8 | 2.3 | · | 3.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 2.7 | 6.5 | · | 1.8 | 0.3 | -2.5 | · | · |
Verimlilik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.4 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.4 | · | 0.4 | |
| Receivables Turnover | 3.1 | 3.2 | · | 4.6 | 3.0 | 3.2 | · | 3.5 | 2.8 | 3.3 | · | 2.3 | 2.3 | 2.8 | · | 2.0 |
Değerleme (TTM) 9
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $358M | $327M | · | $307M | $297M | $287M | · | $260M | $239M | $207M | · | $173M | $141M | $104M | · | $86M | |
| Net Income TTM | $-27M | $5M | · | $33M | $23M | $33M | · | $22M | $5M | $-3M | · | $-28M | $-59M | $-79M | · | $-74M | |
| Market Cap | $1.32B | $757M | · | $1.65B | $1.15B | $1.53B | · | $1.73B | $1.43B | $1.23B | · | $1.11B | $1.09B | $1.08B | · | $813M | |
| P/E | -53.2 | 122.5 | · | 48.8 | 53.4 | 45.7 | · | 78.6 | 261.0 | -453.0 | · | -37.5 | -17.7 | -13.2 | · | -10.7 | |
| P/S | 3.7 | 2.3 | · | 5.4 | 3.9 | 5.3 | · | 6.7 | 6.0 | 5.9 | · | 6.4 | 7.7 | 10.4 | · | 9.5 | |
| P/B | -19.6 | -12.8 | · | -37.0 | -20.8 | -26.1 | · | -8.3 | -6.3 | -5.3 | · | -4.4 | -4.2 | -4.2 | · | -3.4 | |
| P / Cash Flow | · | -141.1 | · | · | · | -239.7 | · | · | · | 183.0 | · | · | · | 937.3 | · | · | |
| P / FCF | · | -104.5 | · | · | · | -227.9 | · | · | · | 285.6 | · | · | · | -151.4 | · | · | |
| Earnings Yield | -1.9% | 0.82% | · | 2.1% | 1.9% | 2.2% | · | 1.3% | 0.38% | -0.22% | · | -2.7% | -5.7% | -7.6% | · | -9.4% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $349M | $286M | $199M | $100M | $75M |
| Faaliyet Kâr Marjı % | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| Net Gelir | $6M | $28M | $-12M | $-87M | $-81M |
| Seyreltilmiş Hisse Başı Kâr | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 |
| Cari Oran | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $14M | $33M | $-8M | $-88M | $-73M |
Son Haberler Bu şirketten bahseden son manşetler
- Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
- MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
- H.C. Wainwright ve Wells Fargo MannKind (MNKD) Fiyat Hedeflerini Yükseltti
- MannKind Corporation (MNKD) Robinhood'ta Satın Alınacak Popüler Bir Senet mi?
İşlem Sinyalleri Giriş fiyatı ve risk/ödül oranı ile son alım/satım sinyalleri
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 271 dosya · $560.6M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 55 (+12 önceki Ç'ye göre) | 37 (-11 önceki Ç'ye göre) | 93 (+10 önceki Ç'ye göre) | 61 (-8 önceki Ç'ye göre) | +24.2M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Rubric Capital Management LP | $76.680.000 | 18.000.000 | 13,68% | Hisse senetleri |
| STATE STREET CORP | $68.901.423 | 16.174.043 | 12,29% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $56.101.610 | 13.169.392 | 10,01% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $29.027.881 | 6.812.460 | 5,18% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $28.116.000 | 6.600.000 | 5,01% | Hisse senetleri |
| Deep Track Capital, LP | $25.560.000 | 6.000.000 | 4,56% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $23.099.232 | 5.422.355 | 4,12% | Hisse senetleri |
| 180 WEALTH ADVISORS, LLC | $21.126.835 | 4.959.351 | 3,77% | Hisse senetleri |
| FMR LLC | $17.455.563 | 4.097.550 | 3,11% | Hisse senetleri |
| TSP Capital Management Group, LLC | $16.923.596 | 3.972.675 | 3,02% | Hisse senetleri |
| BRAIDWELL LP | $14.732.908 | 3.458.429 | 2,63% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.789.240 | 3.002.169 | 2,28% | Hisse senetleri |
| VANGUARD GROUP INC | $11.888.249 | 2.096.693 | 2,12% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $11.475.213 | 2.693.712 | 2,05% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.070.577 | 2.598.727 | 1,97% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $9.358.279 | 2.196.779 | 1,67% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $8.689.749 | 2.039.847 | 1,55% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $6.332.618 | 1.486.530 | 1,13% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.030.221 | 1.180.803 | 0,90% | Hisse senetleri |
| BlackRock, Inc. | $4.766.748 | 1.118.955 | 0,85% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $4.486.321 | 1.053.127 | 0,80% | Hisse senetleri |
| Caption Management, LLC | $4.260.000 | 1.000.000 | 0,76% | Satım opsiyonu |
| J. Goldman & Co LP | $3.478.669 | 816.589 | 0,62% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $3.473.987 | 815.490 | 0,62% | Hisse senetleri |
| SCOPIA CAPITAL MANAGEMENT LP | $2.960.534 | 694.961 | 0,53% | Hisse senetleri |
| Balyasny Asset Management L.P. | $2.914.296 | 684.107 | 0,52% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $2.897.166 | 510.964 | 0,52% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $2.771.407 | 650.565 | 0,49% | Hisse senetleri |
| Swiss National Bank | $2.502.324 | 587.400 | 0,45% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.177.052 | 511.045 | 0,39% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2.106.540 | 494.493 | 0,38% | Hisse senetleri |
| 1492 Capital Management LLC | $2.052.136 | 481.722 | 0,37% | Hisse senetleri |
| Mariner, LLC | $2.020.189 | 474.236 | 0,36% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $1.836.597 | 431.126 | 0,33% | Hisse senetleri |
| Schonfeld Strategic Advisors LLC | $1.774.216 | 416.483 | 0,32% | Hisse senetleri |
| Squarepoint Ops LLC | $1.759.644 | 413.062 | 0,31% | Hisse senetleri |
| Jefferies Financial Group Inc. | $1.694.202 | 397.700 | 0,30% | Hisse senetleri |
| ExodusPoint Capital Management, LP | $1.666.261 | 391.141 | 0,30% | Hisse senetleri |
| JANE STREET GROUP, LLC | $1.658.418 | 389.300 | 0,30% | Alım opsiyonu |
| Man Group plc | $1.624.023 | 381.226 | 0,29% | Hisse senetleri |
| RHUMBLINE ADVISERS | $1.604.647 | 376.681 | 0,29% | Hisse senetleri |
| IEQ CAPITAL, LLC | $1.544.607 | 362.584 | 0,28% | Hisse senetleri |
| CITIGROUP INC | $1.499.243 | 351.935 | 0,27% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.423.692 | 334.200 | 0,25% | Satım opsiyonu |
| Bank of New York Mellon Corp | $1.422.222 | 333.855 | 0,25% | Hisse senetleri |
| Caption Management, LLC | $1.414.231 | 331.979 | 0,25% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $1.359.221 | 319.066 | 0,24% | Hisse senetleri |
| ALPS ADVISORS INC | $1.330.615 | 312.351 | 0,24% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.216.230 | 285.500 | 0,22% | Alım opsiyonu |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.029.075 | 241.567 | 0,18% | Hisse senetleri |
| BARCLAYS PLC | $1.029.062 | 241.564 | 0,18% | Hisse senetleri |
| Rafferty Asset Management, LLC | $1.008.640 | 236.770 | 0,18% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $1.002.715 | 235.379 | 0,18% | Hisse senetleri |
| Aaron Wealth Advisors LLC | $1.000.878 | 234.948 | 0,18% | Hisse senetleri |
| HSBC HOLDINGS PLC | $998.560 | 230.881 | 0,18% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $930.294 | 379.712 | 0,17% | Hisse senetleri |
| CITADEL ADVISORS LLC | $928.680 | 218.000 | 0,17% | Alım opsiyonu |
| CITADEL ADVISORS LLC | $898.860 | 211.000 | 0,16% | Satım opsiyonu |
| Bruce & Co., Inc. | $831.011 | 195.073 | 0,15% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $775.060 | 181.939 | 0,14% | Hisse senetleri |
| MetLife Investment Management, LLC | $766.442 | 179.916 | 0,14% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $755.021 | 177.235 | 0,13% | Hisse senetleri |
| Stonepine Capital Management, LLC | $750.000 | 250.000 | 0,13% | Alım opsiyonu |
| UBS Group AG | $715.978 | 168.070 | 0,13% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $693.375 | 283.010 | 0,12% | Hisse senetleri |
| MORGAN STANLEY | $651.282 | 152.883 | 0,12% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $640.657 | 150.389 | 0,11% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $632.009 | 148.359 | 0,11% | Hisse senetleri |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $613.437 | 171.372 | 0,11% | Hisse senetleri |
| Jain Global LLC | $604.673 | 141.942 | 0,11% | Hisse senetleri |
| KING LUTHER CAPITAL MANAGEMENT CORP | $590.457 | 138.605 | 0,11% | Hisse senetleri |
| Susquehanna Portfolio Strategies, LLC | $574.538 | 134.868 | 0,10% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $570.354 | 133.886 | 0,10% | Hisse senetleri |
| MERCER GLOBAL ADVISORS INC /ADV | $557.723 | 130.921 | 0,10% | Hisse senetleri |
| PROFUND ADVISORS LLC | $517.726 | 121.532 | 0,09% | Hisse senetleri |
| Invesco Ltd. | $512.389 | 120.279 | 0,09% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $509.833 | 119.679 | 0,09% | Hisse senetleri |
| KLP KAPITALFORVALTNING AS | $491.604 | 115.400 | 0,09% | Hisse senetleri |
| Gotham Asset Management, LLC | $452.463 | 106.212 | 0,08% | Hisse senetleri |
| State of New Jersey Common Pension Fund D | $403.171 | 94.641 | 0,07% | Hisse senetleri |
| State of Wyoming | $403.149 | 94.636 | 0,07% | Hisse senetleri |
| Police & Firemen's Retirement System of New Jersey | $386.834 | 90.806 | 0,07% | Hisse senetleri |
| Amundi | $374.310 | 87.866 | 0,07% | Hisse senetleri |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $373.478 | 87.671 | 0,07% | Hisse senetleri |
| NEW YORK STATE COMMON RETIREMENT FUND | $359.966 | 84.499 | 0,06% | Hisse senetleri |
| ARIZONA STATE RETIREMENT SYSTEM | $344.050 | 80.763 | 0,06% | Hisse senetleri |
| Mitsubishi UFJ Asset Management Co., Ltd. | $338.155 | 79.379 | 0,06% | Hisse senetleri |
| Aquatic Capital Management LLC | $335.300 | 78.709 | 0,06% | Hisse senetleri |
| Rockefeller Capital Management L.P. | $332.996 | 78.168 | 0,06% | Hisse senetleri |
| Vanguard Investments Australia, Ltd. | $314.929 | 73.927 | 0,06% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $313.658 | 127.763 | 0,06% | Hisse senetleri |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $312.203 | 73.287 | 0,06% | Hisse senetleri |
| Sequoia Financial Advisors, LLC | $296.935 | 69.703 | 0,05% | Hisse senetleri |
| INTECH INVESTMENT MANAGEMENT LLC | $284.653 | 66.820 | 0,05% | Hisse senetleri |
| COMMONWEALTH EQUITY SERVICES, LLC | $280.421 | 65.827 | 0,05% | Hisse senetleri |
| China Universal Asset Management Co., Ltd. | $262.714 | 61.670 | 0,05% | Hisse senetleri |
| LPL Financial LLC | $260.060 | 61.047 | 0,05% | Hisse senetleri |
| SIMPLEX TRADING, LLC | $258.790 | 60.749 | 0,05% | Hisse senetleri |
| Cetera Investment Advisers | $241.546 | 56.701 | 0,04% | Hisse senetleri |
| Painted Porch Advisors LLC | $227.620 | 53.432 | 0,04% | Hisse senetleri |
Şirket yöneticileri 43 içeriden öğrenenler · 27 yöneticiler · 18 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 15 Temmuz 2026 M | 2.433.779 | 1 | 4 | $-990.292 |
| Hakan Edstrom | President & CEO | 27 Ağustos 2015 A | 1.114.340 | 0 | 0 | $0 |
| Christopher B Prentiss | Chief Financial Officer | 15 Temmuz 2026 F | 318.668 | 0 | 0 | $0 |
| Juergen Martens | Corporate VP and COO | 27 Ağustos 2015 A | 106.539 | 0 | 0 | $0 |
| Dominic Marasco | Pres, Endocrine Business Unit | 15 Temmuz 2026 F | 343.398 | 0 | 0 | $0 |
| Sanjay R Singh | EVP Technical Operations | 15 Temmuz 2026 M | 478.966 | 0 | 1 | $-94.448 |
| Stuart A Tross | Chief People & Workpl Officer | 15 Temmuz 2026 M | 1.058.142 | 0 | 2 | $-548.528 |
| David Thomson | EVP Genl Counsel & Secretary | 15 Temmuz 2026 M | 797.554 | 0 | 3 | $-930.755 |
| Ajay Ahuja | Chief Medical Officer | 23 Mart 2026 A | 318.200 | 0 | 0 | $0 |
| Lauren M Sabella | EVP Operations | 15 Temmuz 2025 F | 349.841 | 0 | 0 | $0 |
| Burkhard Blank | EVP Chief Medical Officer | 15 Temmuz 2025 F | 460.791 | 0 | 0 | $0 |
| Joseph Kocinsky | Chief Technology Officer | 27 Ağustos 2022 F | 745.233 | 0 | 0 | $0 |
| Alejandro Galindo | EVP Endocrine Business Unit | 28 Şubat 2022 A | 576.690 | 0 | 0 | $0 |
| Rosabel Realica Alinaya | VP, IR & Treasury | 27 Ağustos 2020 A | 167.119 | 0 | 0 | $0 |
| David M Kendall | Chief Medical Officer | 31 Temmuz 2020 P | 41.059 | 0 | 0 | $0 |
| Patrick Mccauley | Chief Commercial Officer | 25 Şubat 2020 A | 83.972 | 0 | 0 | $0 |
| Courtney Barton | Chief Compl & Privacy Officer | 31 Temmuz 2019 P | 29.584 | 0 | 0 | $0 |
| Elizabeth Garrett Ingram | Chief Marketing Officer | 14 Mayıs 2019 A | 43.012 | 0 | 0 | $0 |
| Raymond W. Urbanski | Corp VP, CMO | 10 Ağustos 2017 S | 2.924 | 0 | 0 | $0 |
| Linda A Adreveno | Sr. VP, HR | 18 Şubat 2016 A | 92.200 | 0 | 0 | $0 |
| Alfred E Mann | Executive Chairman | 22 Ağustos 2015 F | 1.005.990 | 0 | 0 | $0 |
| Diane Palumbo | Vice President, Human Resource | 23 Şubat 2015 F | 50.624 | 0 | 0 | $0 |
| Peter C Richardson | Chief Scientific Officer | 03 Mart 2012 F | 133.611 | 0 | 0 | $0 |
| Richard L Anderson | Corporate VP | 16 Kasım 2008 F | 204.401 | 0 | 0 | $0 |
| John R. Riesenberger | VP & Chief Commercial Officer | 13 Ağustos 2008 A | 14.650 | 0 | 0 | $0 |
| Dan Burns | VP & President, MKBP | 08 Aralık 2006 A | 14.800 | 0 | 0 | $0 |
| Wendell W Cheatham | VP, Medical & Reg Affairs | 19 Ağustos 2004 A | 300 | 0 | 0 | $0 |
| Sabrina Kay | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 265.600 | 0 | 0 | $0 |
| Jennifer Grancio | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 244.815 | 0 | 0 | $0 |
| James Samuel Shannon | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 64.635 | 0 | 0 | $0 |
| Michael A Friedman | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 47.500 | 0 | 0 | $0 |
| Anthony C Hooper | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 236.153 | 0 | 0 | $0 |
| Christine Mundkur | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 254.493 | 0 | 0 | $0 |
| Ronald J Consiglio | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 132.342 | 0 | 0 | $0 |
| Kent Kresa | Yönetim kurulu üyesi | 15 Mayıs 2024 A | 274.541 | 0 | 0 | $0 |
| Henry L Nordhoff | Yönetim kurulu üyesi | 14 Mayıs 2019 A | 103.426 | 0 | 0 | $0 |
| David Maccallum | Yönetim kurulu üyesi | 16 Mayıs 2018 A | 114.790 | 0 | 0 | $0 |
| Matthew J Pfeffer | Yönetim kurulu üyesi | 28 Ağustos 2017 F | 81.961 | 0 | 0 | $0 |
| Abraham E Cohen | Yönetim kurulu üyesi | 17 Ağustos 2012 S | 56.424 | 0 | 0 | $0 |
| Heather Hay Murren | Yönetim kurulu üyesi | 13 Ağustos 2008 A | 10.100 | 0 | 0 | $0 |
| Kathleen Connell | Yönetim kurulu üyesi | 25 Mayıs 2006 A | — | 0 | 0 | $0 |
| Llew Keltner | Yönetim kurulu üyesi | 25 Mayıs 2006 A | — | 0 | 0 | $0 |
| Steven B. Binder | — | 07 Ağustos 2026 S | 785.867 | 0 | 3 | $-427.369 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 2 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 başvurular | 10 Temmuz 2012 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 31 Ocak 2006 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 41 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| RNIN · EA Series Trust | 1,43% | 773.251 NS | 30 Nisan 2026 | N-PORT |
| SBIO · ALPS ETF Trust | 0,74% | 317.578 NS | 31 Mayıs 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,54% | 29.662 SH | 08 Ağustos 2026 | Günlük |
| AGNG · Global X Funds | 0,46% | 98.947 NS | 31 Mayıs 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,34% | 625.921 NS | 30 Nisan 2026 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0,11% | 64.525 NS | 31 Mayıs 2026 | N-PORT |
| IBB · iShares Trust | 0,09% | 2.170.137 SH | 08 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,09% | 16.814 SH | 08 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 330.117 SH | 08 Ağustos 2026 | Günlük |
| IWO · iShares Trust | 0,07% | 2.772.931 SH | 08 Ağustos 2026 | Günlük |
| ESML · iShares Trust | 0,06% | 449.515 SH | 08 Ağustos 2026 | Günlük |
| BIB · ProShares Trust | 0,06% | 11.389 NS | 31 Mayıs 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 114.273 NS | 30 Nisan 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 1.771.496 SH | 08 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,04% | 7.830.029 SH | 08 Ağustos 2026 | Günlük |
| ISCG · iShares Trust | 0,04% | 94.032 SH | 08 Ağustos 2026 | Günlük |
| ITWO · ProShares Trust | 0,03% | 14.400 NS | 31 Mayıs 2026 | N-PORT |
| RSSL · Global X Funds | 0,03% | 132.607 NS | 30 Nisan 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,02% | 1.466.402 NS | 31 Mayıs 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 61.465 NS | 31 Mayıs 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,02% | 874.372 SH | 08 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | 0,02% | 13.557 SH | 08 Ağustos 2026 | Günlük |
| UWM · ProShares Trust | 0,02% | 11.261 NS | 31 Mayıs 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 135.688 NS | 30 Nisan 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 638.128 NS | 30 Nisan 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 11.390 NS | 31 Mayıs 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 3.543.398 SH | 08 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,01% | 16.464 SH | 08 Ağustos 2026 | Günlük |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 12.000 NS | 31 Mayıs 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 286 NS | 31 Mayıs 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 452.118 NS | 30 Nisan 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 27.701 NS | 30 Nisan 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 1.330 NS | 31 Mayıs 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 465.445 SH | 08 Ağustos 2026 | Günlük |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 196.006 NS | 31 Mayıs 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 83.220 SH | 08 Ağustos 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 10.345 NS | 30 Nisan 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 32.093 NS | 30 Nisan 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 14.557 NS | 30 Nisan 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9.327.332 SH | 08 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 26.184 SH | 08 Ağustos 2026 | Günlük |